A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors

NCT ID: NCT01358227

Last Updated: 2011-05-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-12-31
• Study Completion Date: 2010-01-31

Brief Summary

The purpose of this study is to determine the side effects and best weekly dose of PR104 in patients with advanced solid tumors.

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

PR104

Group Type: EXPERIMENTAL

PR104

Intervention Type: DRUG

Dose escalation of PR104 to determine maximum tolerated dose for weekly administration

Interventions

PR104

Dose escalation of PR104 to determine maximum tolerated dose for weekly administration

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age 18 years or more
• Histologically confirmed malignancy for which no effective therapy exists
• Measurable or evaluable disease
• ECOG Performance Status of 0 or 1. See Section 15.1 (ECOG performance status) for definition of ECOG Performance Status 0 and 1
• Ability to read, understand and provide written informed consent
• If the subject is on systemic steroids, the dose of steroids must be stable for at least two weeks prior to the first dose of PR-104

Exclusion Criteria

• Licensed or investigational anti-cancer therapy (including radiotherapy) within four weeks of the baseline disease assessment (within six weeks for nitrosoureas and Mitomycin C). Subjects on androgen deprivation therapy are allowed on study and may continue to receive androgen deprivation therapy while one study
• Prior radiotherapy to more than 25% of bone marrow; prior high-dose chemotherapy (including either myeloablative or non-myeloablative transplants); or prior receipt of more than three chemotherapy regimens
• Absolute neutrophil count of < 1.5 x 109/L
• Platelet count of < 100 x 109/L
• Hemoglobin level of < 90 g/L (or requiring a red blood cell transfusion to maintain hemoglobin > 90 g/L)
• Serum bilirubin greater than the upper limit of normal
• ALT and AST greater than 2.5 times the upper limit of normal
• Serum creatinine less than 1.5 times upper limit of normal
• Prothrombin time (PT-INR) or activated partial thromboplastin time (APTT) greater than 1.1 times the upper limit of normal range
• Women who are pregnant, breast-feeding or planning to become pregnant during the study
• Men or women of reproductive-potential who are unwilling to use an effective method of contraception during the study and for 30 days following the last dose of study medication. See section 5.11 (Contraceptives) for definition of effective methods of contraception
• Evidence of any other significant medical disorder or laboratory finding that in the opinion of the Investigator compromises the subject's safety during study participation, including uncontrolled infection or infection requiring a concomitant parenteral antibiotic
• Plans for concomitant anti-cancer therapy (excluding androgen deprivation therapy) while on study
• Less than four weeks since major surgery
• Known to be HIV positive, Hepatitis B sAg positive or Hepatitis C positive with abnormal liver function tests
• No known contraindication to single doses of naproxen

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Proacta, Incorporated

INDUSTRY

Sponsor Role: lead

Responsible Party

Proacta, Inc.

Principal Investigators

Mark McKeage, PhD, FRACP

Role: PRINCIPAL_INVESTIGATOR

University of Auckland, New Zealand

Locations

University of Auckland

Auckland, , New Zealand

Waikato Hospital

Waikato, , New Zealand

Countries

New Zealand

Other Identifiers

PR104-1002

Identifier Type: -

Identifier Source: org_study_id